Current and emerging drug treatments for binge eating disorder

Expert Opinion on Emerging Drugs

Volumn 19, Issue 1, 2014, Pages 99-142

  Reas, Deborah L ^a   Grilo, Carlos M ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Binge eating; Medication; Obesity; Pharmacotherapy; Placebo

Indexed keywords

ACAMPROSATE; AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; ATOMOXETINE; BACLOFEN; CITALOPRAM; DESIPRAMINE; DRUGS USED IN THE TREATMENT OF ADDICTION; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LAMOTRIGINE; LISDEXAMFETAMINE; METHYLPHENIDATE; NALOXONE; PLACEBO; RIMONABANT; SAMIDORPHAN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNINDEXED DRUG; ZONISAMIDE;

BINGE EATING DISORDER; DEPRESSION; DISEASE ASSOCIATION; HUMAN; MEDICATION THERAPY MANAGEMENT; MENTAL DISEASE; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; WEIGHT REDUCTION;

BINGE-EATING DISORDER; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEPRESSION; HUMANS; WEIGHT LOSS;

EID: 84896703654     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2014.879291     Document Type: Review

References (65)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. American Psychiatric Publishing, Arlington, VA, USA; 2013
2. Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007;61(3):348-58
3. Marques L, Alegria M, Becker AE, et al. Comparative prevalence, correlates of impairment, and service utilization for eating disorders across US ethnic groups: implications for reducing ethnic disparities in health care access for eating disorders. Int J Eat Disord 2011;44(5):412-20
4. Johnson JG, Spitzer RL, Williams JB. Health problems, impairment and illnesses associated with bulimia nervosa and binge eating disorder among primary care and obstetric gynaecology patients. Psychol Med 2001;31(8):1455-66
5. Grilo CM, White MA, Masheb RM. DSM-IV psychiatric disorder comorbidity and its correlates in binge eating disorder. Int J Eat Disord 2009;42(3):228-34
6. Grilo CM, Crosby RD, Masheb RM, et al. Overvaluation of shape and weight in binge eating disorder, bulimia nervosa, and sub-threshold bulimia nervosa. Behav Res Ther 2009;47(8):692-6
7. Grilo CM, Hrabosky JI, White MA, et al. Overvaluation of shape and weight in binge eating disorder and overweight controls: refinement of a diagnostic construct. J Abnorm Psychol 2008;117(2):414-19
8. Hudson JI, Lalonde JK, Berry JM, et al. Binge-eating disorder as a distinct familial phenotype in obese individuals. Arch Gen Psychiatry 2006;63(3):313-19
9. Allison KC, Grilo CM, Masheb RM, Stunkard AJ. Binge eating disorder and night eating syndrome: a comparative study of disordered eating. J Consult Clin Psychol 2005;73(6):1107-15
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Author; Washington, DC, USA: 1994
11. Wilson GT, Grilo CM, Vitousek KM. Psychological treatment of eating disorders. Am Psychol 2007;62(3):199-216
12. Wilson GT. Treatment of binge eating disorder. Psychiatr Clin North Am 2011;34(4):773-83
13. Grilo CM, Masheb RM, Wilson GT, et al. Cognitive-behavioral therapy, behavioral weight loss, and sequential treatment for obese patients with bingeeating disorder: a randomized controlled trial. J Consult Clin Psychol 2011;79(5):675-85
14. Wilson GT, Wilfley DE, Agras WS, Bryson SW. Psychological treatments of binge eating disorder. Arch Gen Psychiatry 2010;67(1):94-101
15. Hilbert A, Bishop ME, Stein RI, et al. Long-term efficacy of psychological treatments for binge eating disorder. Br J Psychiatry 2012;200(3):232-7
16. McElroy SL, Guerdjikova AI, Mori N, O'Melia AM. Pharmacological management of binge eating disorder: current and emerging treatment options. Ther Clin Risk Manag 2012;8:219-41
17. Reas DL, Grilo CM. Review and metaanalysis of pharmacotherapy for bingeeating disorder. Obesity (Silver Spring) 2008;16(9):2024-38
18. Aigner M, Treasure J, Kaye W, Kasper S. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry 2011;12(6):400-43
19. National Institute for Clinical Excellence. Eating disorders: core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. (Clinical Guideline No. 9), National Institute for Clinical Excellence London: 2004
20. Stunkard A, Berkowitz R, Tanrikut C, et al. d-fenfluramine treatment of binge eating disorder. Am J Psychiatry 1996;153(11):1455-9
21. Appolinario JC, Bacaltchuk J, Sichieri R, et al. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry 2003;60(11):1109-16
22. Milano W, Petrella C, Casella A, et al. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study. Adv Ther 2005;22(1):25-31
23. Wilfley DE, Crow SJ, Hudson JI, et al. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled doubleblind study. Am J Psychiatry 2008;165(1):51-8
24. Bauer C, Fischer A, Keller U. Effect of sibutramine and of cognitive-behavioural weight loss therapy in obesity and subclinical binge eating disorder. Diabetes Obes Metab 2006;8(3):289-95
25. Pataky Z, Gasteyger C, Ziegler O, et al. Efficacy of rimonabant in obese patients with binge eating disorder. Exp Clin Endocrinol Diabetes 2013;121(1):20-6
26. Corwin RL, Boan J, Peters KF, Ulbrecht JS. Baclofen reduces binge eating in a double-blind, placebocontrolled, crossover study. Behav Pharmacol 2012;23(5-6):616-25
27. Marcus MD, Wing RR, Ewing L, et al. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry 1990;147(7):876-81
28. McCann UD, Agras WS. Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled study. Am J Psychiatry 1990;147(11):1509-13
29. Greeno CG, Wing RR. A double-blind, placebo-controlled trial of the effect of fluoxetine on dietary intake in overweight women with and without binge-eating disorder. Am J Clin Nutr 1996;64(3):267-73
30. Alho H, Lahti T, Appleberg B, et al. Opioid antagonist naloxone nasal spray treatment for patients with binge eating disorder (BED): a randomized, controlled trial. Paper presented at the 166th annual meeting of the American Psychiatric Association; San Francisco, CA; 2013
31. McElroy SL, Mitchell JE, Wilfley DE, et al. Lisdexamfetamine dimesylate safety and efficacy on binge eating days/episodes and behavior in adults with moderate to severe binge eating disorder. Paper presented at the 166th annual meeting of the American Psychiatric Association; San Francisco, CA; 2013
32. Arnold LM, McElroy SL, Hudson JI, et al. A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry 2002;63(11):1028-33
33. Devlin MJ, Goldfein JA, Petkova E, et al. Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. Obes Res 2005;13(6):1077-88
34. Devlin MJ, Goldfein JA, Petkova E, et al. Cognitive behavioral therapy and fluoxetine for binge eating disorder: twoyear follow-up. Obesity (Silver Spring) 2007;15(7):1702-9
35. Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized doubleblind placebo-controlled comparison. Biol Psychiatry 2005;57(3):301-9
36. Grilo CM, Crosby RD, Wilson GT, Masheb RM. 12-month follow-up of fluoxetine and cognitive behavioral therapy for binge eating disorder. J Consult Clin Psychol 2012;80(6):1108-13
37. Leombruni P, Piero A, Lavagnino L, et al. A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(6):1599-605
38. Ricca V, Mannucci E, Mezzani B, et al. Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study. Psychother Psychosom 2001;70(6):298-306
39. Hudson JI, McElroy SL, Raymond NC, et al. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry 1998;155(12):1756-62
40. McElroy SL, Casuto LS, Nelson EB, et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry 2000;157(6):1004-6
41. McElroy SL, Hudson JI, Malhotra S, et al. Citalopram in the treatment of binge-eating disorder: a placebocontrolled trial. J Clin Psychiatry 2003;64(7):807-13
42. Guerdjikova AI, McElroy SL, Kotwal R, et al. High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. Hum Psychopharmacol 2008;23(1):1-11
43. Guerdjikova AI, McElroy SL, Winstanley EL, et al. Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial. Int J Eat Disord 2012;45(2):281-9
44. White MA, Grilo CM. Buproprion for overweight women with binge eating disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2013;74(4):400-6
45. Laederach-Hofmann K, Graf C, Horber F, et al. Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: a randomized, placebo-controlled doubleblind study. Int J Eat Disord 1999;26(3):231-44
46. Agras WS, Rossiter EM, Arnow B, et al. One-year follow-up of psychosocial and pharmacologic treatments for bulimia nervosa. J Clin Psychiatry 1994;55(5):179-83
47. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003;160(2):255-61
48. McElroy SL, Hudson JI, Capece JA, et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 2007;61(9):1039-48 . Large multi-site RCT reporting short-term efficacy of topiramate relative to placebo for both binge-eating and weight.
49. Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry 2007;68(9):1324-32 . RCT reporting that the addition of topiramate to CBT significantly enhanced short-term weight loss.
50. McElroy SL, Shapira NA, Arnold LM, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry 2004;65(11):1463-9
51. Guerdjikova AI, McElroy SL, Welge JA, et al. Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial. Int Clin ?Psychopharmacol 2009;24(3):150-8
52. McElroy SL, Kotwal R, Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 2006;67(12):1897-906
53. Golay A, Laurent-Jaccard A, Habicht F, et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res 2005;13(10):1701-8
54. Grilo CM, Masheb RM, Salant SL. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry 2005;57(10):1193-201 . RCT reporting that the addition of orlistat to CBT-guided-self-help significantly enhanced short-term weight loss.
55. Grilo CM, White MA. Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as. Behav Res Ther 2013;51(3):167-75
56. McElroy SL, Guerdjikova AI, Winstanley EL, et al. Acamprosate in the treatment of binge eating disorder: a placebo-controlled trial. Int J Eat Disord 2011;44(1):81-90
57. McElroy SL, Guerdjikova AI, Blom TJ, et al. A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. Int J Eat Disord 2013;46(3):239-45
58. McElroy SL, Guerdjikova A, Kotwal R, et al. Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry 2007;68(3):390-8
59. Brownley KA, Von HA, Hamer RM, et al. A double-blind, randomized pilot trial of chromium picolinate for binge eating disorder: results of the Binge Eating and Chromium (BEACh) study. J Psychosom Res 2013;75(1):36-42
60. Franko DL, Thompson-Brenner H, Thompson DR, et al. Racial/ethnic differences in adults in randomized clinical trials of binge eating disorder. J Consult Clin Psychol 2012;80(2):186-95
61. Grilo CM, Masheb RM, Crosby RD. Predictors and moderators of response to cognitive behavioral therapy and medication for the treatment of binge eating disorder. J Consult Clin Psychol 2012;80(5):897-906
62. Grilo CM, Masheb RM, Wilson GT. Rapid response to treatment for binge eating disorder. J Consult Clin Psychol 2006;74(3):602-13 . Important methodological paper documenting the negative prognostic significance of failing to achieve a rapid response to SSRI medication.
63. Walsh BT, Sysko R, Parides MK. Early response to desipramine among women with bulimia nervosa. Int J Eat Disord 2006;39(1):72-5
64. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 2006;63(11):1217-23
65. Pearlstein T, Spurell E, Hohlstein LA, et al. A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response. Arch Womens Ment Health 2003;6(2):147-51